Trial Profile
Equivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Ferric pyrophosphate (Primary) ; Ferric pyrophosphate (Primary)
- Indications Iron metabolism disorders
- Focus Pharmacokinetics; Registrational
- Sponsors Rockwell Medical Technologies
- 07 Nov 2021 Results published in the Journal of Clinical Pharmacology
- 27 Mar 2020 According to a Rockwell Medical India media release, the U.S. Food and Drug Administration (FDA) has approved New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC.
- 06 Aug 2019 According to a Rockwell Medical Technologies media release, based on the results of this study, the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for its Intravenous (I.V.) formulation of TRIFERIC with a PDUFA (Prescription Drug User Fee Act) date of March 28, 2020.